{
    "name": "insulin glargine",
    "comment": "Rx",
    "other_names": [
        "Lantus",
        "Lantus SoloStar",
        "Toujeo",
        "Basaglar",
        "Semglee",
        "insulin glargine-yfgn",
        "Rezvoglar",
        "insulin glargine-aglr"
    ],
    "classes": [
        "Antidiabetics",
        "Insulins",
        "Antidiabetics",
        "Long-Acting Insulins"
    ],
    "source": "https://reference.medscape.com/drug/lantus-toujeo-insulin-glargine-999003",
    "pregnancy": {
        "common": [
            "Published data do not report a clear association with insulin glargine products and major birth defects, miscarriage, or adverse maternal or fetal outcomes when insulin glargine products used during pregnancy; however, these studies cannot definitely establish absence of any risk because of methodological limitations including small sample size and some with no comparative group",
            "There are risks to mother and fetus associated with poorly controlled diabetes in pregnancy; poorly controlled diabetes in pregnancy increases maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, stillbirth, and delivery complications"
        ],
        "specific": [
            {
                "type": "Disease-associated maternal and/or embryo-fetal Risk",
                "description": [
                    "Hypoglycemia and hyperglycemia occur more frequently during pregnancy in patients with pre-gestational diabetes;l poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery, and delivery complications; poorly controlled diabetes increases fetal risk for major birth defects, stillbirth, and macrosomia-related morbidity"
                ]
            },
            {
                "type": "Animal data",
                "description": [
                    "In animal reproduction studies, rats and rabbits were exposed to insulin glargine in animal reproduction studies during organogenesis, respectively 50 times and 10 times the human subcutaneous dose of 0.2 units/kg/day; overall, effects of insulin glargine did not generally differ from those observed with regular human insulin"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence of insulin glargine in human milk, effects on breastfed infant, or on milk production",
            "Use of insulin glargine is compatible with breastfeeding, but women with diabetes who are lactating may require adjustments of their insulin doses; health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from drug or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Documented hypersensitivity to drug or excipients",
                "During episodes of hypoglycemia"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Toujeo and Lantus are not interchangeable",
                "Not recommended for treating diabetic ketoacidosis; use IV short-acting insulin instead",
                "Never share insulin pens between patients, even if the needle is changed; pen sharing poses a risk for transmission of blood-borne pathogens",
                "To avoid dosing errors and potential overdose, never use a syringe to remove drug from TOUJEO SoloStar or TOUJEO Max SoloStar prefilled pen into a syringe",
                "Decreased insulin requirements: Diarrhea, nausea/vomiting, malabsorption, hypothyroidism, renal impairment, hepatic impairment",
                "Increased insulin requirements include fever, hyperthyroidism, trauma, infection, surgery",
                "Increase frequency of glucose monitoring with changes to insulin dosage, coadministered glucose lowering medications, meal pattern, or physical activity; and in patients with renal or hepatic impairment and hypoglycemia unawareness",
                "Accidental mix-ups between insulin products can occur; instruct patients to check insulin labels before injection",
                "Rapid changes in serum glucose may induce symptoms of hypoglycemia",
                "Hypoglycemia is the most common cause of adverse reactions (eg, headache, tachycardia)",
                "May cause a shift in potassium from extracellular to intracellular space, possibly leading to hypokalemia; caution when coadministered with potassium-lowering drugs or conditions that may decrease potassium",
                "Frequent glucose monitoring and insulin dose reduction may be required with renal or hepatic impairment; not recommended during periods of rapidly declining renal or hepatic function because of risk for prolonged hypoglycemia",
                "Exercise caution when administering this therapy to geriatric patients with diabetes; initial dosing, dose increments, and maintenance dosage should be conservative to avoid hypoglycemia",
                "Use caution during pregnancy"
            ],
            "specific": [
                {
                    "type": "Hyperglycemia or hypoglycemia with changes in insulin regimen",
                    "description": [
                        "Changes in insulin, insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia",
                        "Changes should be made cautiously and only under close medical supervision and frequency of blood glucose monitoring should be increased",
                        "Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis reported to result in hyperglycemia; a sudden change in the injection site (to unaffected area) has been reported to result in hypoglycemia",
                        "Make any changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring",
                        "Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change injection site to unaffected areas and closely monitor for hypoglycemia",
                        "For patients with type 2 diabetes, dosage adjustments in concomitant oral antidiabetic treatment may be needed",
                        "Long-acting effect of this medication may delay recovery from hypoglycemia compared to shorter-acting insulins"
                    ]
                },
                {
                    "type": "Cancer risk data inconclusive",
                    "description": [
                        "The FDA reviewed 4 published observational studies, 3 of which suggested an increased risk of cancer associated with insulin glargine",
                        "It was determined that the evidence presented in these studies is inconclusive due to methodologic limitations",
                        "The duration of patient follow-up in all 4 studies was shorter than that which is generally considered necessary to evaluate cancer risk from drug exposure",
                        "Also, the 4 studies provided limited information on patients' use of insulin products; some studies did not take into account whether the patients used any antidiabetic drugs before the study time period or whether there were any changes in how patients used these drugs during the study period",
                        "Furthermore, risk factors for cancer (eg, smoking, family history of cancer, obesity) may not have been adequately controlled for in these studies"
                    ]
                },
                {
                    "type": "Drug interactions overview",
                    "description": [
                        "Thiazolidinediones are peroxisome proliferator-activated receptor (PPAR)-gamma agonists and can cause dose-related fluid retention, particularly when used in combination with insulin; fluid retention may lead to or exacerbate heart failure; monitor for signs and symptoms of heart failure, treat accordingly, and consider discontinuing thiazolidinediones",
                        "Coadministration with these drugs (eg, antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs [eg, octreotide], sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors) may increase the risk of hypoglycemia",
                        "Coadministration with these drugs (eg, atypical antipsychotics [eg, olanzapine and clozapine], corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens [eg, oral contraceptives], protease inhibitors, somatropin, sympathomimetic agents [eg, albuterol, epinephrine, terbutaline], and thyroid hormones) may decrease the risk of hypoglycemia",
                        "Concomitant use of alcohol, beta-blockers, clonidine, and lithium salts with insulin glargine may increase or decrease blood glucose lowering effect of insulin glargine",
                        "Pentamidine may cause hypoglycemia, which may sometimes be followed with hyperglycemia",
                        "Coadministration with beta-blockers, clonidine, guanethidine, or reserpine may blunt signs and symptoms of hypoglycemia"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "pramlintide",
            "description": {
                "common": "insulin glargine, pramlintide. Mechanism: unspecified interaction mechanism. Contraindicated. Must be administered separately."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ethanol",
            "description": {
                "common": "ethanol, insulin glargine. Other (see comment). Avoid or Use Alternate Drug. \nComment: Alcohol may either increase or decrease the blood glucose lowering effect of insulin; alcohol may decrease endogenous glucose production (increased hypoglycemia risk) or worsen glycemic control by adding calories."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "macimorelin",
            "description": {
                "common": "insulin glargine, macimorelin. unspecified interaction mechanism. Avoid or Use Alternate Drug. Drugs that may transiently elevate growth hormone (GH) concentrations may impact the accuracy of the macimorelin diagnostic test. Allow sufficient washout time of drugs affecting GH release before administering macimorelin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acarbose",
            "description": {
                "common": "acarbose, insulin glargine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "albiglutide",
            "description": {
                "common": "albiglutide, insulin glargine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alogliptin",
            "description": {
                "common": "alogliptin, insulin glargine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "aripiprazole, insulin glargine. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine",
            "description": {
                "common": "asenapine, insulin glargine. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin",
            "description": {
                "common": "aspirin increases effects of insulin glargine by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atazanavir",
            "description": {
                "common": "atazanavir decreases effects of insulin glargine by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azilsartan",
            "description": {
                "common": "azilsartan increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benazepril",
            "description": {
                "common": "benazepril increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypoglycemic effects; Monitor blood glucose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bexagliflozin",
            "description": {
                "common": "bexagliflozin increases effects of insulin glargine by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin to avoid hypoglycemia when coadministered with bexagliflozin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bitter melon",
            "description": {
                "common": "bitter melon increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "canagliflozin",
            "description": {
                "common": "insulin glargine, canagliflozin.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with canagliflozin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "candesartan",
            "description": {
                "common": "candesartan increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "captopril",
            "description": {
                "common": "captopril increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor.  Both drugs decrease blood glucose. Monitor blood glucose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpropamide",
            "description": {
                "common": "chlorpropamide, insulin glargine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cinnamon",
            "description": {
                "common": "cinnamon increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor. Potential for hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ciprofibrate",
            "description": {
                "common": "ciprofibrate increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clozapine",
            "description": {
                "common": "clozapine, insulin glargine. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dapagliflozin",
            "description": {
                "common": "insulin glargine, dapagliflozin.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with dapagliflozin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "darunavir",
            "description": {
                "common": "darunavir decreases effects of insulin glargine by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deflazacort",
            "description": {
                "common": "insulin glargine and deflazacort both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexfenfluramine",
            "description": {
                "common": "dexfenfluramine increases effects of insulin glargine by Other (see comment). Use Caution/Monitor. \nComment: Dexfenfluramine enhances glucose uptake in peripheral tissue, increasing risk of hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide and insulin glargine both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "disopyramide",
            "description": {
                "common": "disopyramide increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and disopyramide may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dulaglutide",
            "description": {
                "common": "dulaglutide, insulin glargine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "empagliflozin",
            "description": {
                "common": "empagliflozin, insulin glargine.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with SGLT2 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enalapril",
            "description": {
                "common": "enalapril increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eprosartan",
            "description": {
                "common": "eprosartan increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ertugliflozin",
            "description": {
                "common": "ertugliflozin, insulin glargine.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with ertugliflozin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethinylestradiol",
            "description": {
                "common": "ethinylestradiol decreases effects of insulin glargine by pharmacodynamic antagonism. Use Caution/Monitor. Oral contraceptives may decrease hypoglycemic effects of antidiabetics by impairing glucose tolerance. Monitor for glycemic control in diabetic patients."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "exenatide injectable solution",
            "description": {
                "common": "exenatide injectable solution, insulin glargine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "exenatide injectable suspension",
            "description": {
                "common": "exenatide injectable suspension, insulin glargine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenfluramine",
            "description": {
                "common": "fenfluramine increases effects of insulin glargine by Other (see comment). Use Caution/Monitor. \nComment: Fenfluramine enhances glucose uptake in peripheral tissue, increasing risk of hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenofibrate",
            "description": {
                "common": "fenofibrate increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenofibrate micronized",
            "description": {
                "common": "fenofibrate micronized increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenofibric acid",
            "description": {
                "common": "fenofibric acid increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fleroxacin",
            "description": {
                "common": "fleroxacin increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "fluoxetine increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and fluoxetine may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosamprenavir",
            "description": {
                "common": "fosamprenavir decreases effects of insulin glargine by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosinopril",
            "description": {
                "common": "fosinopril increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gemfibrozil",
            "description": {
                "common": "gemfibrozil increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gemifloxacin",
            "description": {
                "common": "gemifloxacin increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glimepiride",
            "description": {
                "common": "glimepiride, insulin glargine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glipizide",
            "description": {
                "common": "glipizide, insulin glargine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glucagon",
            "description": {
                "common": "glucagon decreases effects of insulin glargine by pharmacodynamic antagonism. Use Caution/Monitor. Endogenous glucagon is a regulatory hormone that increases blood glucose levels; exogenous glucagon is often used to treat hypoglycemia in patients with diabetes mellitus."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glucagon intranasal",
            "description": {
                "common": "glucagon intranasal decreases effects of insulin glargine by pharmacodynamic antagonism. Use Caution/Monitor. Endogenous glucagon is a regulatory hormone that increases blood glucose levels; exogenous glucagon is often used to treat hypoglycemia in patients with diabetes mellitus."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glyburide",
            "description": {
                "common": "glyburide, insulin glargine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iloperidone",
            "description": {
                "common": "iloperidone, insulin glargine. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imidapril",
            "description": {
                "common": "imidapril increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indinavir",
            "description": {
                "common": "indinavir decreases effects of insulin glargine by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "irbesartan",
            "description": {
                "common": "irbesartan increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isocarboxazid",
            "description": {
                "common": "isocarboxazid increases effects of insulin glargine by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketotifen, ophthalmic",
            "description": {
                "common": "ketotifen, ophthalmic, insulin glargine. Other (see comment). Use Caution/Monitor. \nComment: Combination may result in thrombocytopenia (rare).  Monitor CBC."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lanreotide",
            "description": {
                "common": "lanreotide increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and somatostatin analogs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levofloxacin",
            "description": {
                "common": "levofloxacin increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "linagliptin",
            "description": {
                "common": "linagliptin, insulin glargine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "linezolid",
            "description": {
                "common": "linezolid increases effects of insulin glargine by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "liraglutide",
            "description": {
                "common": "liraglutide, insulin glargine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lisinopril",
            "description": {
                "common": "lisinopril increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lithium",
            "description": {
                "common": "lithium, insulin glargine. unspecified interaction mechanism. Use Caution/Monitor. Lithium salts may cause either hypoglycemia or hyperglycemia. Insulin dosage adjustment and increased glucose monitoring may be required."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lixisenatide (DSC)",
            "description": {
                "common": "lixisenatide (DSC), insulin glargine.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Risk of hypoglycemia increased when coadministered with basal insulins. Basal insulin dose reduction may be required."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lonapegsomatropin",
            "description": {
                "common": "lonapegsomatropin decreases effects of insulin glargine by Other (see comment). Use Caution/Monitor. \nComment: Closely monitor blood glucose when treated with antidiabetic agents. Lonapegsomatropin may decrease insulin sensitivity, particularly at higher doses. Patients with diabetes mellitus may require adjustment of their doses of insulin and/or other antihyperglycemic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lopinavir",
            "description": {
                "common": "lopinavir decreases effects of insulin glargine by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "losartan",
            "description": {
                "common": "losartan increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lurasidone",
            "description": {
                "common": "lurasidone, insulin glargine. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "magnesium salicylate",
            "description": {
                "common": "magnesium salicylate increases effects of insulin glargine by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "marijuana",
            "description": {
                "common": "marijuana decreases effects of insulin glargine by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mecasermin",
            "description": {
                "common": "mecasermin increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metformin",
            "description": {
                "common": "metformin, insulin glargine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methyltestosterone",
            "description": {
                "common": "methyltestosterone increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor. It is important to monitor all patients with type 2 diabetes on antidiabetic agents receiving androgens for changes in glycemic control. Potential for hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metoclopramide intranasal",
            "description": {
                "common": "metoclopramide intranasal increases effects of insulin glargine by Other (see comment). Use Caution/Monitor. \nComment: Increased GI motility by metoclopramide may increase delivery of food to the intestines and increase blood glucose. Monitor blood glucose and adjust insulin dosage regimen as needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metreleptin",
            "description": {
                "common": "insulin glargine, metreleptin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of metreleptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "miglitol",
            "description": {
                "common": "miglitol, insulin glargine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "moexipril",
            "description": {
                "common": "moexipril increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "moxifloxacin",
            "description": {
                "common": "moxifloxacin increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nadolol",
            "description": {
                "common": "nadolol, insulin glargine. Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers delay recovery of normoglycemia after insulin induced hypoglycemia; however, they also inhibit insulin secretion, so long term beta blocker Tx may result in reduced glucose tolerance.  Insulin induced hypoglycemia may induce hypertension during non selective beta blocker Tx."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nateglinide",
            "description": {
                "common": "nateglinide, insulin glargine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "nelfinavir decreases effects of insulin glargine by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "niacin",
            "description": {
                "common": "niacin decreases effects of insulin glargine by pharmacodynamic antagonism. Use Caution/Monitor. Concomitant use of insulin and niacin may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "octreotide",
            "description": {
                "common": "octreotide increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and somatostatin analogs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ofloxacin",
            "description": {
                "common": "ofloxacin increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olanzapine",
            "description": {
                "common": "olanzapine, insulin glargine. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olmesartan",
            "description": {
                "common": "olmesartan increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "opuntia ficus indica",
            "description": {
                "common": "opuntia ficus indica increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paliperidone",
            "description": {
                "common": "paliperidone, insulin glargine. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pasireotide",
            "description": {
                "common": "pasireotide increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and somatostatin analogs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentamidine",
            "description": {
                "common": "pentamidine, insulin glargine. unspecified interaction mechanism. Use Caution/Monitor. Pentamidine may cause either hypoglycemia or hyperglycemia followed by the opposing effect. Insulin dosage adjustment and increased glucose monitoring may be required."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "perindopril",
            "description": {
                "common": "perindopril increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenelzine",
            "description": {
                "common": "phenelzine increases effects of insulin glargine by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pindolol",
            "description": {
                "common": "pindolol, insulin glargine. Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers delay recovery of normoglycemia after insulin induced hypoglycemia; however, they also inhibit insulin secretion, so long term beta blocker Tx may result in reduced glucose tolerance.  Insulin induced hypoglycemia may induce hypertension during non selective beta blocker Tx."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pioglitazone",
            "description": {
                "common": "insulin glargine increases toxicity of pioglitazone by unknown mechanism. Use Caution/Monitor. Insulin may increase the fluid retention associated with thiazolidinediones (peroxisome proliferator-activated receptor [PPAR]-gamma agonists)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "procarbazine",
            "description": {
                "common": "procarbazine increases effects of insulin glargine by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propranolol",
            "description": {
                "common": "propranolol, insulin glargine. Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers delay recovery of normoglycemia after insulin induced hypoglycemia; however, they also inhibit insulin secretion, so long term beta blocker Tx may result in reduced glucose tolerance.  Insulin induced hypoglycemia may induce hypertension during non selective beta blocker Tx."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pseudoephedrine",
            "description": {
                "common": "pseudoephedrine decreases effects of insulin glargine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Sympathomimetics increase blood glucose by stimulating alpha and beta receptors; this action results in increased hepatic glucose production, glycogenolysis, and decreased insulin secretion."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quetiapine",
            "description": {
                "common": "quetiapine, insulin glargine. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinapril",
            "description": {
                "common": "quinapril increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ramipril",
            "description": {
                "common": "ramipril increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rasagiline",
            "description": {
                "common": "rasagiline increases effects of insulin glargine by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "risperidone",
            "description": {
                "common": "risperidone, insulin glargine. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir decreases effects of insulin glargine by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rosiglitazone",
            "description": {
                "common": "insulin glargine increases toxicity of rosiglitazone by unknown mechanism. Use Caution/Monitor. Insulin may increase the fluid retention associated with thiazolidinediones (peroxisome proliferator-activated receptor [PPAR]-gamma agonists)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sacubitril/valsartan",
            "description": {
                "common": "sacubitril/valsartan increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salsalate",
            "description": {
                "common": "salsalate increases effects of insulin glargine by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir decreases effects of insulin glargine by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saxagliptin",
            "description": {
                "common": "saxagliptin, insulin glargine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "selegiline",
            "description": {
                "common": "selegiline increases effects of insulin glargine by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "semaglutide",
            "description": {
                "common": "semaglutide, insulin glargine.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with GLP-1 agonists may increase hypoglycemia risk. Lowering the insulin dose may reduce hypoglycemia risk."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "shark cartilage",
            "description": {
                "common": "shark cartilage increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor. Theoretical interaction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sitagliptin",
            "description": {
                "common": "sitagliptin, insulin glargine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/?magnesium sulfate/potassium chloride",
            "description": {
                "common": "sodium sulfate/?magnesium sulfate/potassium chloride increases toxicity of insulin glargine by Other (see comment). Use Caution/Monitor. \nComment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/potassium sulfate/magnesium sulfate",
            "description": {
                "common": "sodium sulfate/potassium sulfate/magnesium sulfate increases toxicity of insulin glargine by Other (see comment). Use Caution/Monitor. \nComment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol",
            "description": {
                "common": "insulin glargine and sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol both decrease  serum potassium. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "somapacitan",
            "description": {
                "common": "somapacitan decreases effects of insulin glargine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Growth hormone products may decrease insulin sensitivity, particularly at higher doses. Antidiabetic agents may require dose adjustment after initiating somapacitan. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "somatropin",
            "description": {
                "common": "somatropin decreases effects of insulin glargine by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfadiazine",
            "description": {
                "common": "sulfadiazine increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and sulfonamide antibiotics may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfamethoxypyridazine",
            "description": {
                "common": "sulfamethoxypyridazine increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfisoxazole",
            "description": {
                "common": "sulfisoxazole increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and sulfonamide antibiotics may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "telmisartan",
            "description": {
                "common": "telmisartan increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "testosterone intranasal",
            "description": {
                "common": "testosterone intranasal increases effects of insulin glargine by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Androgens may decrease blood glucose and, therefore, may necessitate a decrease in the dose of antidiabetic medication."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "timolol",
            "description": {
                "common": "timolol, insulin glargine. Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers delay recovery of normoglycemia after insulin induced hypoglycemia; however, they also inhibit insulin secretion, so long term beta blocker Tx may result in reduced glucose tolerance.  Insulin induced hypoglycemia may induce hypertension during non selective beta blocker Tx."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tipranavir",
            "description": {
                "common": "tipranavir decreases effects of insulin glargine by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolazamide",
            "description": {
                "common": "tolazamide, insulin glargine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolbutamide",
            "description": {
                "common": "tolbutamide, insulin glargine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trandolapril",
            "description": {
                "common": "trandolapril increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tranylcypromine",
            "description": {
                "common": "tranylcypromine increases effects of insulin glargine by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triamcinolone acetonide injectable suspension",
            "description": {
                "common": "triamcinolone acetonide injectable suspension decreases effects of insulin glargine by pharmacodynamic antagonism. Use Caution/Monitor.  Corticosteroids may diminish hypoglycemic effect of antidiabetic agents. Monitor blood glucose levels carefully."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valsartan",
            "description": {
                "common": "valsartan increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "xipamide",
            "description": {
                "common": "xipamide decreases levels of insulin glargine by increasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ziprasidone",
            "description": {
                "common": "ziprasidone, insulin glargine. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "agrimony",
            "description": {
                "common": "agrimony increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "American ginseng",
            "description": {
                "common": "American ginseng increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amitriptyline",
            "description": {
                "common": "amitriptyline increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amoxapine",
            "description": {
                "common": "amoxapine increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "anamu",
            "description": {
                "common": "anamu increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. Theoretical interaction."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aspirin/citric acid/sodium bicarbonate",
            "description": {
                "common": "aspirin/citric acid/sodium bicarbonate increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. Large dose of salicylate."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "balsalazide",
            "description": {
                "common": "balsalazide increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. Large dose of salicylate."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bendroflumethiazide",
            "description": {
                "common": "bendroflumethiazide decreases effects of insulin glargine by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bexarotene",
            "description": {
                "common": "bexarotene increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "budesonide",
            "description": {
                "common": "budesonide decreases effects of insulin glargine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorothiazide",
            "description": {
                "common": "chlorothiazide decreases effects of insulin glargine by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorthalidone",
            "description": {
                "common": "chlorthalidone decreases effects of insulin glargine by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chromium",
            "description": {
                "common": "chromium increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clomipramine",
            "description": {
                "common": "clomipramine increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clonidine",
            "description": {
                "common": "clonidine, insulin glargine. Other (see comment). Minor/Significance Unknown. \nComment: Decreased symptoms of hypoglycemia.  Mechanism: decreased hypoglycemia induced catecholamine production."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "coenzyme Q10",
            "description": {
                "common": "coenzyme Q10 increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. Monitor insulin requirements."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cornsilk",
            "description": {
                "common": "cornsilk increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cortisone",
            "description": {
                "common": "cortisone decreases effects of insulin glargine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclopenthiazide",
            "description": {
                "common": "cyclopenthiazide decreases effects of insulin glargine by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "damiana",
            "description": {
                "common": "damiana decreases effects of insulin glargine by pharmacodynamic antagonism. Minor/Significance Unknown. Theoretical interaction."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "danazol",
            "description": {
                "common": "danazol increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "deflazacort",
            "description": {
                "common": "deflazacort decreases effects of insulin glargine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "desipramine",
            "description": {
                "common": "desipramine increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "devil's claw",
            "description": {
                "common": "devil's claw increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "dexamethasone decreases effects of insulin glargine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diflunisal",
            "description": {
                "common": "diflunisal increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. Large dose of salicylate."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "doxepin",
            "description": {
                "common": "doxepin increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "elderberry",
            "description": {
                "common": "elderberry increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (in vitro research)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "eucalyptus",
            "description": {
                "common": "eucalyptus increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. Theoretical interaction."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fludrocortisone",
            "description": {
                "common": "fludrocortisone decreases effects of insulin glargine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fluoxymesterone",
            "description": {
                "common": "fluoxymesterone increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fo-ti",
            "description": {
                "common": "fo-ti increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "forskolin",
            "description": {
                "common": "forskolin increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. Colenol, a compound found in Coleus root, may stimulate insulin release."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "gotu kola",
            "description": {
                "common": "gotu kola increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "guanfacine",
            "description": {
                "common": "guanfacine, insulin glargine. Other (see comment). Minor/Significance Unknown. \nComment: Decreased symptoms of hypoglycemia.  Mechanism: decreased hypoglycemia induced catecholamine production."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "gymnema",
            "description": {
                "common": "gymnema increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "horse chestnut seed",
            "description": {
                "common": "horse chestnut seed increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydrochlorothiazide",
            "description": {
                "common": "hydrochlorothiazide decreases effects of insulin glargine by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydrocortisone",
            "description": {
                "common": "hydrocortisone decreases effects of insulin glargine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "imipramine",
            "description": {
                "common": "imipramine increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "indapamide",
            "description": {
                "common": "indapamide decreases effects of insulin glargine by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "isoniazid",
            "description": {
                "common": "isoniazid decreases effects of insulin glargine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "juniper",
            "description": {
                "common": "juniper increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lofepramine",
            "description": {
                "common": "lofepramine increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lycopus",
            "description": {
                "common": "lycopus increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "maitake",
            "description": {
                "common": "maitake increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (animal research)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "maprotiline",
            "description": {
                "common": "maprotiline increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "mesalamine",
            "description": {
                "common": "mesalamine increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. Large dose of salicylate."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "mesterolone",
            "description": {
                "common": "mesterolone increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methylprednisolone",
            "description": {
                "common": "methylprednisolone decreases effects of insulin glargine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metolazone",
            "description": {
                "common": "metolazone decreases effects of insulin glargine by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nettle",
            "description": {
                "common": "nettle increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nortriptyline",
            "description": {
                "common": "nortriptyline increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ofloxacin",
            "description": {
                "common": "ofloxacin, insulin glargine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "oxandrolone",
            "description": {
                "common": "oxandrolone increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "oxymetholone",
            "description": {
                "common": "oxymetholone increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "panax ginseng",
            "description": {
                "common": "panax ginseng increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pegvisomant",
            "description": {
                "common": "pegvisomant increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "potassium acid phosphate",
            "description": {
                "common": "potassium acid phosphate increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "potassium chloride",
            "description": {
                "common": "potassium chloride increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "potassium citrate",
            "description": {
                "common": "potassium citrate increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "prednisolone",
            "description": {
                "common": "prednisolone decreases effects of insulin glargine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "prednisone",
            "description": {
                "common": "prednisone decreases effects of insulin glargine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "protriptyline",
            "description": {
                "common": "protriptyline increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sage",
            "description": {
                "common": "sage increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "salicylates (non-asa)",
            "description": {
                "common": "salicylates (non-asa) increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. Large dose of salicylate."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "Siberian ginseng",
            "description": {
                "common": "Siberian ginseng increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sulfasalazine",
            "description": {
                "common": "sulfasalazine increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. Large dose of salicylate."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "testosterone",
            "description": {
                "common": "testosterone increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "testosterone buccal system",
            "description": {
                "common": "testosterone buccal system increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "testosterone topical",
            "description": {
                "common": "testosterone topical increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tongkat ali",
            "description": {
                "common": "tongkat ali increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypoglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "trazodone",
            "description": {
                "common": "trazodone increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "trimipramine",
            "description": {
                "common": "trimipramine increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vanadium",
            "description": {
                "common": "vanadium increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "willow bark",
            "description": {
                "common": "willow bark increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown. Large dose of salicylate."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Rhinitis",
            "percent": null
        }
    ]
}